Gradient Investments’s ADC Therapeutics ADCT Stock Holding History

Gradient Investments’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11	Closed	-$35	–	308
2024 Q2	$35	Buy	+11	New	+$44	﹤0.01%	1347

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Gradient Investments's ADCT Position: Q3 2024 in Review

Gradient Investments sold out of ADC Therapeutics (ADCT) in Q3 2024, closing a stake of 11 shares — an estimated $35 sold.

Gradient Investments first reported a position in ADCT in Q2 2024 and held it in 1 quarter. The position peaked at $35 in Q2 2024. 77 funds tracked by Wall St. Rank hold ADCT as of Q3 2024.

Gradient Investments reported no remaining ADC Therapeutics position as of Q3 2024 after selling out during the quarter.
Gradient Investments sold 11 ADC Therapeutics shares in Q3 2024, an estimated $35.
Gradient Investments first reported a position in ADC Therapeutics in Q2 2024 and held it in 1 quarter.
Gradient Investments's ADC Therapeutics position peaked at $35 in Q2 2024.
77 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2024.

Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.